Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AVAIL-T: Avelumab in Relapsed/Refractory PTCL
NCT03046953Phase 2Completed
- Sponsor
- University of Birmingham
- Start
- Dec 2017
- Primary completion
- Jul 2020
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of avelumab in peripheral T-cell lymphoma (PTCL), sponsored by University of Birmingham. Started Dec 2017; status: completed.
02
Drugs
avelumab
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on NCT03046953.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03046953.